JTL
BCRX icon

Jupiter Topco LLC’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jupiter Topco LLC’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95.3M Buy
+9,540,764
New +$86.3M 0.04% 315

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jupiter Topco LLC's BCRX Position: Q2 2026 in Review

Jupiter Topco LLC opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 9,540,764 shares worth $95.3M. The stake represents 0.04% of the portfolio and ranks #315 among its holdings.

296 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Jupiter Topco LLC held 9,540,764 shares of BioCryst Pharmaceuticals worth $95.3M as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Jupiter Topco LLC position in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.04% of Jupiter Topco LLC's portfolio in Q2 2026, its #315 holding.
  • 296 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Jupiter Topco LLC's 13F filing for Q2 2026, filed 14 Aug 2026.